The ASCO Annual meeting runs from June 7, 2021 to June 8, 2021. I am happy to once again attend this meeting which shares cancer research from across the globe. I wish it was in person but once more we will be meeting virtually.
This year's theme is EQUITY: EVERY PATIENT EVERY DAY EVERY WHERE.
Here is a list of the sessions that relate to Gynecologic Cancer that I hope to attend.
I have also made a list of a few abstracts of research that I would like to learn more about so I don't miss out on the discussion during the meetings sessions or online.
ORAL ABSTRACTS
5502 Oral Abstract
Session
Maintenance vigil
immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment
of homologous recombination proficient (HRP) patients in the phase IIb VITAL
trial. Abstract 5502 (Vigil, an autologous tumor cell vaccine
transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin for TGFβ
expression control, following frontline platinum-based chemotherapy)
5501 Oral Abstract
Session
Optimal treatment duration of bevacizumab (BEV) combined
with carboplatin and paclitaxel in patients (pts) with primary epithelial
ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter
open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group,
GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890). (BEV treatment duration of 15 months remains standard of care vs 30 months)
5504
Mirvetuximab soravtansine, a folate receptor alpha
(FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab
in patients (pts) with platinum-agnostic ovarian cancer: Final analysis 5504
The combination of MIRV with BEV demonstrates impressive anti-tumor
activity with durable responses and favorable tolerability in high FRα
recurrent ovarian cancer.
5503 Oral Abstract Session
Phase 3, randomized,
single-dose, open-label study to investigate the safety and efficacy of
pafolacianine sodium injection (OTL38) for intraoperative imaging of folate
receptor positive ovarian cancer. intraoperative near-infrared fluores-
cence (NIRF) imaging with pafolacianine sodium may offer a novel real-time
adjunct to current surgical imaging practice in ovarian cancer surgery.
5506 Oral Abstract Session
Intensive versus
minimalist follow-up in patients treated for endometrial cancer: A multicentric
randomized controlled trial (The TOTEM study—NCT00916708). Intensive
follow-up in endometrial cancer treated patients showed a weak and uncertain
advantage in detecting earlier asymptomatic relapses but did not improve OS,
even in HiR patients, nor influenced HRQL.
POSTERS:
5513 Poster Discussion
Session
Evaluation of a RAD51
functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. RAD51-deficient EOC have im- proved outcome
after neoadjuvant platinum. Conversely, the RAD51 assay also identified a small
subset of RAD51-high BRCAmut tumors with poor platinum response. Whether
this RAD51 functional assay may also predict PARP inhibitor benefit is
currently
5519 Poster Discussion
Session
Molecular results and
potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of
binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-
grade serous ovarian cancer (LGSOC). higher response rates and longer PFS were
seen in those patients with LGSOC treated with binimetinib who harbored MAPK
mutations, most commonly in KRAS. Somatic tu- mor testing should be
routinely performed in patients with recurrent LGSOC to aid in clinical
decision making.
5521 Poster Discussion
Session
Dendritic cell vaccine
(DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed
epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS):
Biomarker exploratory analysis of a phase 2, open-label, randomized,
multicenter trial. DCVAC
improved PFS and OS outcomes in patients with newly diag- nosed EOC,
predominantly in patients with immunologically “cold” tumors,
5544 Poster Session
Nanoanalysis of plasma
volatile organic compounds using novel DNA-decorated carbon nanotube vapor
sensors to noninvasively distinguish ovarian and pancreatic cancer from benign
and control samples. Prescreening
test diagnostic
approach based on vapor detection of ovarian and pancreatic cancer is
achievable.
5548 Poster Session
Circulating tumor DNA
as a noninvasive marker of resectability in ovarian carcinomas. ctDNA may be a
promising non-invasive marker to assess peritoneal cancer spreading and to
predict surgical resectability after neoadjuvant chemotherapy
5553 Poster Session
Next generation
sequencing in ovarian cancer patients: Does personalized medicine improve
oncological outcomes? Our study suggests an OS benefit among the NGS tested
cohort. We identified Loss of heterozygosity as a prognostic biomarker
5552 Poster Session- Disparities
Disparities in ovarian
cancer treatment and overall survival according to race: An update. Overall survival
remains worse for black patients, regardless of whether their care adhered to
NCCN guidelines as defined by our study. This suggests that while receipt of
care that is not adherent to NCCN guidelines seems to be negatively associated
with overall survival,
5571 Poster Session- Disparities
Race-related
disparities in patterns of uterine cancer recurrence. non-White race is
potentially contributory to distant recurrence of uterine can- cer, even when
accounting for histopathologic differences, stage at presentation, and other
traditional covariates.
Have you looked at the abstracts? Did some catch your eye? Please let me know and tag me ( @womenofteal in a tweet). Please be sure to use #gyncsm when you are tweeting from the meeting too.
I'll catch you all up on what I have learned with a few posts about this year's meeting. Stay tuned!
Dee
Every Day is a Blessing!
